United States securities and exchange commission logo





                             August 12, 2020

       Charles Wilson, Ph.D.
       President and Chief Executive Officer
       Unum Therapeutics Inc.
       200 Cambridge Park Drive, Suite 3100
       Cambridge, Massachusetts 02140

                                                        Re: Unum Therapeutics
Inc.
                                                            Preliminary Proxy
Statement on Schedule 14A
                                                            Filed July 30, 2020
                                                            File No. 001-38443

       Dear Dr. Wilson:

             We have reviewed your filing and have the following comment. In
our comment, we
       may ask you to provide us with information so we may better understand
your disclosure.

              Please respond to our comment within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comment applies to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to our comment, we may have additional comments.

       Preliminary Proxy Statement on Schedule 14A

       Proposal No. 1, page 8

   1.                                                   Please revise your
disclosure to provide the information required by Items 11, 13 and 14
                                                        with respect to the Kiq
Bio LLC acquisition and the private placement of Series A
                                                        preferred stock. Refer
to Note A of Schedule 14A.
 Charles Wilson, Ph.D.
FirstName LastNameCharles    Wilson, Ph.D.
Unum Therapeutics  Inc.
Comapany
August 12, NameUnum
           2020         Therapeutics Inc.
August
Page 2 12, 2020 Page 2
FirstName LastName
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Please contact Tim Buchmiller at (202) 551-3635 or Celeste Murphy at
(202) 551-3257
with any questions.



                                                          Sincerely,

                                                          Division of
Corporation Finance
                                                          Office of Life
Sciences
cc:      Andrew H. Goodman, Esq.